Exploring Drug Delivery to the Peritoneum

The Peritoneal cavity (PC) is the key metastatic site for intra-abdominal malignancies (e.g., GI tract and rectal cancer). PC sites can be used tötarget several other diseases where lymphatic drug delivery is desired without dumping large amounts of the drug. Until recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS), heated intraperitoneal chemotherapy (HIPEC), and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy for cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding of the role of drug delivery systems in targeting drugs in the intraperitoneal (IP) cavity. There are two main challenges posed to such therapies 1) the complexity of IP cavity and 2) the drug transport dynamics e.g., the residence time of small molecular weight drugs, the fate of delivery systems (both nano and micro), etc. The present book is a link between pharmaceutical scientists (drug formulators), clinicians, and toxicologists. This book also provides a new perspective töresearchers tödivert or guide their research in an optimal way. Exploring Drug Delivery töthe Peritoneum serves as a platform for upcoming technologies especially in the medical devices sector töface up and show potential in delivering drugs to IP cavity. It is a chance for commercial partners like insurance companies and the pharma industry töexplore the old administration route in a new way.

Auteur

Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. For the last many years, she has been working with various multinational pharmaceutical companies in technical/R&D leadership roles. Currently, she serves as a Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research at numerous national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited several trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received numerous prestigious national and international awards among them include recently received the prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting, and the role of excipients in delivery systems (www.ranjitas.com).